TP53 and prostate carcinoma: XR-4 showed comparable cancer cell proliferation inhibition activity and lower off-target toxicity compared to those of RG7388 in a broad of spectrum p53 wild-type cancer cells, including liver cancer, prostate cancer, breast cancer, bladder cancer, and colorectal cancer cells.